VACCINEX INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
VCNX$1.41-61.4%Stored close · as of Dec 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity (Deficit) (Unaudited)
(in thousands, except share data)
| Preferred Stock · Common Stock · Treasury Stock | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · AdditionalPaid-inCapital · CommonStockShares · Amount · AccumulatedDeficit · TotalStockholders’Equity/(Deficit) | |||||||||||
| Balance as of January 1, 2023 | - | $ | - | 237,532 | $ | - | $324,880 | 5 | $(11) | $(319,676) | $5,193 |
| Issuance of common stock | - | - | 23,693 | - | 2,040 | - | - | - | 2,040 | ||
| Stock-based compensation | - | - | - | - | 129 | - | - | - | 129 | ||
| Net loss | - | - | - | - | - | - | - | (4,962) | (4,962) | ||
| Balance as of March 31, 2023 | - | - | 261,225 | - | 327,049 | 5 | (11) | (324,638) | 2,400 | ||
| Issuance of Common Shares | - | - | 51,486 | - | 4,111 | - | - | - | 4,111 | ||
| Stock-based compensation | - | - | - | - | 126 | - | - | - | 126 | ||
| Net loss | - | - | - | - | - | - | - | (7,060) | (7,060) | ||
| Balance as of June 30, 2023 | - | $ | - | 312,711 | $ | - | $331,286 | 5 | $(11) | $(331,698) | $(423) |
| Preferred Stock · Common Stock · Treasury Stock | |||||||||||
| Shares · Amount · Shares · Amount · AdditionalPaid-inCapital · CommonStockShares · Amount · AccumulatedDeficit · TotalStockholders’Equity/(Deficit) | |||||||||||
| Balance as of January 1, 2024 | - | $ | - | 892,622 | $ | - | $337,627 | 5 | $(11) | $(339,927) | $(2,311) |
| Issuance of common stock | - | - | 64,816 | - | 2 | - | - | - | 2 | ||
| Stock-based compensation | - | - | - | - | 96 | - | - | - | 96 | ||
| Issuance of common stock and pre-funded warrants in private placement offerings | - | - | 626,867 | 1 | 4,223 | - | - | - | 4,224 | ||
| Issuance of warrants in private placement offerings | - | - | - | - | 750 | - | - | - | 750 | ||
| Issuance of warrants | - | - | - | - | 556 | - | - | - | 556 | ||
| Issuance of preferred stock | 10 | 1,236 | - | - | - | - | - | - | 1,236 | ||
| Reclassification of public warrants, as amended | - | - | - | - | 1,199 | - | - | - | 1,199 | ||
| Reclassification of private placement warrants, as amended | - | - | - | - | 800 | - | - | - | 800 | ||
| Net loss | - | - | - | - | - | - | - | (3,897) | (3,897) | ||
| Balance as of March 31, 2024 | 10 | 1,236 | 1,584,305 | 1 | 345,253 | 5 | (11) | (343,824) | 2,655 | ||
| Stock-based compensation | - | - | - | - | 112 | - | - | - | 112 | ||
| Amortization of preferred stock discount | - | 143 | - | - | (143) | - | - | - | - | ||
| Issuance of restricted stock | - | - | 543 | - | - | - | - | - | - | ||
| Net loss | - | - | - | - | - | - | - | (5,631) | (5,631) | ||
| Balance as of June 30, 2024 | 10 | $1,379 | 1,584,848 | $1 | $345,222 | 5 | $(11) | $(349,455) | $(2,864) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.